The KCNE2 gene plays a crucial role in cardiac electrophysiology, influencing the function of potassium channels that are critical for the proper electrical activity of the heart. Mutations in the KCNE2 gene can lead to Long QT Syndrome type 6 (LQT6), a rare inherited condition characterized by prolonged repolarization of the heart after a heartbeat. This condition increases the risk of irregular heartbeats (arrhythmias), fainting, and sudden death, especially under stress or during exercise.
To diagnose LQT6, a genetic test focusing on the KCNE2 gene can be conducted. This test involves analyzing the DNA to identify mutations in the KCNE2 gene that are known to cause the syndrome. DNA Labs UAE offers this specific genetic testing service for individuals who are at risk of LQT6 due to their family history or those who exhibit symptoms related to abnormal heart rhythms.
The cost of the KCNE2 gene Long QT syndrome type 6 genetic test at DNA Labs UAE is 4400 AED. The test provides a crucial diagnostic tool for affected individuals and their families, enabling them to understand their risk for developing LQT6. With this knowledge, patients can take preventive measures, such as lifestyle adjustments and possibly medication, under the guidance of a healthcare professional to manage their condition effectively and reduce the risk of life-threatening cardiac events.
The CACNA1C gene is implicated in Long QT Syndrome type 8, a rare genetic disorder that affects the heart's electrical activity, leading to potentially dangerous arrhythmias. The condition is characterized by prolonged repolarization of the heart after a heartbeat, which is visible on an electrocardiogram (ECG) as a prolonged QT interval. This can lead to symptoms such as fainting, seizures, or even sudden cardiac death.
To diagnose this specific subtype of Long QT Syndrome, a genetic test targeting the CACNA1C gene is utilized. This test identifies mutations in the CACNA1C gene that are responsible for the condition, providing crucial information for the diagnosis, management, and familial screening of affected individuals.
In the UAE, DNA Labs offers this specialized genetic test for Long QT Syndrome type 8. The cost of the test is 4400 AED. DNA Labs UAE is known for its state-of-the-art facilities and expertise in genetic diagnostics, offering accurate and reliable results. The test is conducted under strict quality controls, ensuring that individuals and their healthcare providers receive critical information for the effective management of the condition. This test is not only pivotal for confirming the diagnosis but also plays a significant role in guiding treatment decisions and preventive measures for patients and their families.
The CAV3 gene Long QT syndrome type 9 genetic test is a specialized diagnostic tool designed to identify mutations in the CAV3 gene, which are associated with Long QT Syndrome type 9 (LQT9). Long QT Syndrome is a disorder of the heart's electrical system, characterized by prolonged QT intervals on an ECG, which can lead to sudden, uncontrollable arrhythmias and potentially fatal cardiac events. The CAV3 gene plays a critical role in the structure and function of heart muscle cells, and mutations in this gene can disrupt the heart's electrical activity, leading to the symptoms of LQT9.
This genetic test is crucial for individuals with a family history of Long QT Syndrome or unexplained sudden cardiac deaths, as it can help in the early diagnosis and management of the condition. Early detection through genetic testing allows for the implementation of lifestyle changes, medical interventions, and possibly preventatives measures for at-risk family members, significantly reducing the risk of life-threatening cardiac events.
The test is available at DNA Labs UAE, a leading facility in genetic testing and diagnostics, ensuring high standards of accuracy and reliability. The cost of the CAV3 gene Long QT syndrome type 9 genetic test is 4400 AED, reflecting the sophisticated technology and expertise required to perform this specialized diagnostic procedure. By opting for this test at DNA Labs UAE, individuals can gain crucial insights into their genetic predisposition to LQT9, enabling informed decisions about their health and preventive care.
The FBN1 Gene Marfan Syndrome Genetic Test is a specialized diagnostic procedure offered at DNA Labs UAE, designed to identify mutations in the FBN1 gene, which are associated with Marfan syndrome. Marfan syndrome is a genetic disorder that affects the body's connective tissue, leading to symptoms in various systems, including the skeletal, cardiovascular, and ocular systems. The test is crucial for individuals with a family history of Marfan syndrome or those exhibiting symptoms, as early detection can lead to better management and treatment of the condition. The cost of the test is 4400 AED, reflecting the comprehensive analysis and expertise required to accurately interpret the results. Conducted in the state-of-the-art facilities of DNA Labs UAE, this genetic test provides individuals and families with essential information for making informed health decisions.
The FBN1 Gene MASS Syndrome Genetic Test is a specialized diagnostic tool available at DNA Labs UAE, designed to identify mutations in the FBN1 gene, which are associated with MASS syndrome. MASS syndrome is a connective tissue disorder that shares similarities with Marfan syndrome, affecting the body's eyes, heart, bones, and skin. The condition is named after its main features: Myopia, Aortic enlargement, Skin and Skeletal abnormalities.
This genetic test is crucial for individuals showing symptoms of MASS syndrome or those with a family history of connective tissue disorders. Early detection through this test can lead to better management and treatment plans, potentially reducing the risk of complications such as aortic dissection.
DNA Labs UAE offers this comprehensive test for a cost of 4400 AED. The process involves collecting a DNA sample, typically through a blood draw, which is then analyzed for mutations in the FBN1 gene. Results from this test can provide valuable information for both patients and healthcare providers, facilitating informed decisions regarding surveillance and management of the condition.
The "MYLK2 Gene Cardiomyopathy Hypertrophic Midventricular Digenic Genetic Test" is a specialized diagnostic evaluation offered by DNA Labs UAE, designed to identify mutations in the MYLK2 gene that are associated with a specific form of hypertrophic cardiomyopathy (HCM). HCM is a condition characterized by the thickening of the heart muscle, which can lead to various cardiac issues, including heart failure and arrhythmias. The midventricular form of HCM involves thickening in the middle part of the heart muscle, which can impede normal blood flow and affect heart function.
This genetic test is particularly significant because it recognizes the digenic inheritance pattern, which means that mutations in more than one gene are contributing to the condition. The MYLK2 gene, one of the genes involved, plays a crucial role in muscle contraction and has been linked to the development of HCM. Identifying mutations in this gene can be crucial for understanding the risk and potential progression of the disease in patients and their families.
The test is priced at 4400 AED and is conducted at DNA Labs UAE, a facility known for its advanced genetic testing services. By opting for this test, individuals can gain valuable insights into their genetic predisposition to developing hypertrophic cardiomyopathy, enabling them to make informed decisions about their health management and treatment options. It also aids in the early detection and intervention of the disease, potentially improving the quality of life and outcomes for those affected.
The "MT-TG Gene Cardiomyopathy Hypertrophic MT-TG Related Genetic Test" is a specialized diagnostic procedure aimed at identifying mutations in the MT-TG gene, which are associated with hypertrophic cardiomyopathy (HCM). HCM is a condition characterized by the thickening of the heart muscle, which can lead to various cardiac issues, including heart failure and sudden cardiac death. The test is particularly vital for individuals with a family history of HCM or those exhibiting symptoms related to heart muscle disorders.
Performed at DNA Labs UAE, this genetic test involves analyzing the patient's DNA to detect specific mutations in the MT-TG gene that are linked to the development of hypertrophic cardiomyopathy. The test's accuracy and specificity make it a crucial tool for early diagnosis, allowing for timely intervention and management of the condition.
The cost of the MT-TG Gene Cardiomyopathy Hypertrophic MT-TG Related Genetic Test is set at 4400 AED. This investment covers the comprehensive analysis required to ascertain the presence of the genetic mutation. By identifying individuals at risk, this test plays a pivotal role in the preventive healthcare strategy against hypertrophic cardiomyopathy, offering a proactive approach to managing and potentially mitigating the impact of this genetic heart condition.
The PLN Gene Cardiomyopathy Hypertrophic Type 18 Genetic Test is a specialized diagnostic tool designed to detect mutations in the PLN gene, which are associated with Hypertrophic Cardiomyopathy (HCM) Type 18. This condition is characterized by the thickening of the heart muscle, which can lead to heart failure and other serious complications. The test is particularly valuable for individuals with a family history of HCM or those exhibiting symptoms related to heart muscle dysfunction.
Conducted at DNA Labs UAE, a leading facility in genetic diagnostics, the test offers a comprehensive analysis of the PLN gene to identify specific genetic alterations that contribute to the development of this form of cardiomyopathy. The process involves collecting a DNA sample from the patient, usually through a blood draw, and then utilizing advanced genetic sequencing technologies to scrutinize the PLN gene for any mutations.
The cost of the PLN Gene Cardiomyopathy Hypertrophic Type 18 Genetic Test is 4400 AED. This investment covers the entire testing process, from sample collection to detailed genetic analysis and reporting. The results from this test can provide crucial information for the diagnosis, treatment planning, and management of hypertrophic cardiomyopathy, enabling personalized medical care and potentially improving patient outcomes.
Given the implications of identifying a genetic predisposition to HCM, patients are often advised to undergo genetic counseling before and after the test. This ensures they fully understand the potential outcomes and implications of the test results, including the impact on family members who may also be at risk.
The MT-TH Gene Cardiomyopathy Idiopathic Dilated Mitochondrial MT-TH Related Genetic Test is a specialized diagnostic assessment offered by DNA Labs UAE. This test is designed to identify mutations in the MT-TH gene, which have been associated with idiopathic dilated cardiomyopathy, a condition characterized by the heart's diminished ability to pump blood due to an enlarged and weakened left ventricle. Mitochondrial genetic factors like those involving the MT-TH gene play a crucial role in the energy production processes of heart muscle cells. Identifying mutations in this gene can provide essential insights into the underlying genetic causes of cardiomyopathy, enabling more personalized and effective treatment strategies.
The test is conducted using a sample of the patient's blood or saliva, where DNA is extracted and analyzed for specific genetic variations in the MT-TH gene that are known to contribute to the development of cardiomyopathy. The cost of the test is 4400 AED, reflecting the sophisticated technology and expertise required to accurately identify these genetic markers.
By opting for the MT-TH Gene Cardiomyopathy Idiopathic Dilated Mitochondrial MT-TH Related Genetic Test at DNA Labs UAE, patients and healthcare providers can gain valuable genetic information that may impact treatment decisions, risk assessment for family members, and overall management of the condition.
The "MT-ATP8 Gene Cardiomyopathy Infantile Hypertrophic MT-ATP8 Related Genetic Test" is a specialized diagnostic procedure aimed at identifying mutations in the MT-ATP8 gene, which have been linked to the development of infantile hypertrophic cardiomyopathy. This condition is a severe form of heart disease that manifests early in life, leading to the thickening of the heart's walls and potentially resulting in heart failure or sudden death if not diagnosed and managed promptly. The test is particularly crucial for families with a history of the condition or when the disease is suspected based on clinical symptoms.
Performed at DNA Labs UAE, a leading genetic testing facility, the test involves analyzing the patient's DNA to detect mutations in the MT-ATP8 gene that are responsible for the condition. This gene plays a critical role in the production of ATP synthase, an enzyme vital for energy production within heart muscle cells. Mutations can impair heart function, leading to the symptoms associated with hypertrophic cardiomyopathy.
The cost of the test is 4400 AED, reflecting the sophisticated technology and expertise required to accurately identify the genetic mutations associated with this condition. By opting for this test, patients and their families can gain valuable insights into the genetic basis of the disease, enabling targeted treatment strategies and informed decisions about management and care. Early detection through genetic testing like the MT-ATP8 related test is essential for improving outcomes and quality of life for affected infants.
